Icosavax nabs $51M as synthetic virus heads toward clinic
A new biotech is using an artificial virus-like particle to try to vaccinate against the respiratory syncytial virus (RSV), a flu-like disease for which no vaccination or cure exists.
Icosavax launches with a $51 million Series A financing from Qiming Venture Partners USA, Adams Street Partners, Sanofi Ventures and NanoDimension that will propel it into a Phase I trial for IVX-121, their new vaccine for older adults.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
